Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass.
Exp Diabetes Res
; 2011: 376509, 2011.
Article
em En
| MEDLINE
| ID: mdl-21716694
ABSTRACT
Recent preclinical studies in rodent models of diabetes suggest that exogenous GLP-1R agonists and DPP-4 inhibitors have the ability to increase islet mass and preserve beta-cell function, by immediate reactivation of beta-cell glucose competence, as well as enhanced beta-cell proliferation and neogenesis and promotion of beta-cell survival. These effects have tremendous implication in the treatment of T2D because they directly address one of the basic defects in T2D, that is, beta-cell failure. In human diabetes, however, evidence that the GLP-1-based drugs alter the course of beta-cell function remains to be found. Several questions surrounding the risks and benefits of GLP-1-based therapy for the diabetic beta-cell mass are discussed in this review and require further investigation.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Transdução de Sinais
/
Receptores de Glucagon
/
Diabetes Mellitus Tipo 1
/
Diabetes Mellitus Tipo 2
/
Células Secretoras de Insulina
Limite:
Animals
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Exp Diabetes Res
Assunto da revista:
ENDOCRINOLOGIA
Ano de publicação:
2011
Tipo de documento:
Article
País de afiliação:
França